{"name":"Biopharma Plasma LLC","slug":"biopharma-plasma-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BP-SCIG 20%","genericName":"BP-SCIG 20%","slug":"bp-scig-20","indication":"Primary immunodeficiency disorders requiring immunoglobulin replacement","status":"phase_3"}]}],"pipeline":[{"name":"BP-SCIG 20%","genericName":"BP-SCIG 20%","slug":"bp-scig-20","phase":"phase_3","mechanism":"BP-SCIG 20% is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering immunoglobulin G (IgG) antibodies to patients with primary immunodeficiency.","indications":["Primary immunodeficiency disorders requiring immunoglobulin replacement"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOX0VvS0JHbER2V2QzZExQSEFaTGRpdVBDa1VDek5yc3AweVdiWnBXTDhlVmlJTkFFU3V1M21STGtwa29zeGxOR3ZXeG0yQlhrOFg1ODdZMUNoRzBFdFYwcGJzRVlHdk1LXzhmMlFkNXJsRTN3VGdFSjJtdGdUYnJlb045bzlYZHRYbjljWk5GZlhPRlY3dHJ0MlB4NThTNUlyZC1fQnhqb1JVX252am9oT1htNFliTWNIdnc?oc=5","date":"2026-03-24","type":"regulatory","source":"Reuters","summary":"Grifols approves IPO of its US biopharma business - Reuters","headline":"Grifols approves IPO of its US biopharma business","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPb25Md0I4Zi0zTXNwOHZ5aW9lN3JpTll1dGJIeDJFdndKcDh3QlNUZk5Fb2JpRnM3d09Zd0R4TThuNzM2VVhuN09aRGFMNWdCMVZGakFWNGwyTDdLWm1XQUVhZGUtN3o1ekxUVmtuZlM3WHJlbW8xR0RlM2lEVkw2M19UVjF1c2pHSE5nRi1WdTF3c3l3WUZON0dDVUx3aVpJZTdkQXBMTkM5TUoyclpDVmRwWjduN1JiSGdOSHRNYWZYV0VkRTBj?oc=5","date":"2026-03-10","type":"pipeline","source":"Fierce Pharma","summary":"CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago - Fierce Pharma","headline":"CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKQjVRa3Fjay05WEdjelFUYkNVdVQ5VFFPYk42eGRvLXpTOVJYdHJaTjY4RjE3VHlmOWM0SDV1QmZKNEJXTmg0YVd2eEptbllhaklWQy1vRWdwNC1aUmptb1BfdGZLUQ?oc=5","date":"2026-01-05","type":"regulatory","source":"Fierce Pharma","summary":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products - Fierce Pharma","headline":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNQVJQYzNVWEt1aEZTYnQ5c2VZYnoxTnNkUXpnMHFQcWw0RC1lQy1pWnNKUGVRSzJ0TkNrQlBGbk9LdmJCS0FNRnVfWmJQNzZGZjd2V1hpTXhleWRfMXpQc3RUcG1Qd1lmY3Y4RkpLMl9VOTFBSHZBNHV3VzhxVFpJM0NLaGJjYUhVM1RJdFQtNERJaS1uTkN0TjNtbG1UVjlNclFTMA?oc=5","date":"2025-11-18","type":"pipeline","source":"Fierce Pharma","summary":"CSL charts US plasma manufacturing expansion with $1.5B investment - Fierce Pharma","headline":"CSL charts US plasma manufacturing expansion with $1.5B investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQbTR4T2V3TE9meHlKaWVGdllyYUhYM3dualc0RkhpM2JKTy1pN21ndUZHejRFZkRSVEZsdFVGdVZZOUd3WUJiZzlJMDZXdFJobVAyM05WNmhHbGhDSFhxbUJpakN5YlhyU0pGbDY2ZTc0UUhtamdXb0Y3emIwQWYwSTE5RlRCYVFFWXJqS1NQb01HcElmN2w5LTNBV1BadjROUHBxTmZjVzVKY19KMzFuQmotU3BvQ0xJUmtNODNxWQ?oc=5","date":"2025-10-06","type":"pipeline","source":"MassLive","summary":"Massachusetts’ largest biopharma employer Takeda to lay off 137 people in Cambridge with cell therapy cuts - MassLive","headline":"Massachusetts’ largest biopharma employer Takeda to lay off 137 people in Cambridge with cell therapy cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQVUdzWUp2OXBodUk0TmNIS1VScW5PdXpCeTBvZWF3Y1FqSVhxWHhDVGFxS3J3TjBGZHVRdlVRaXlyNGprZEhQU2FMTlFjVGpMUUI2Z3dqdUJlUTktTXJCRWptRzBYQlcxeFZiWXRkYkt2bWJMdDFscjE5SWstRzh5S3lWQ1NqbGRRSDF2MWFjdXVPQ0lFMHlGZTNpZGhtSk90djB5bWV4cUVfVkFoU3ZaYlRtZ1d2dEdhdHc?oc=5","date":"2025-09-29","type":"regulatory","source":"Fierce Pharma","summary":"Italian plasma specialist Kedrion reveals US investment plan after gaining FDA nod for Qivigy - Fierce Pharma","headline":"Italian plasma specialist Kedrion reveals US investment plan after gaining FDA nod for Qivigy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQcXNwNmtjZ3dTd3lQd1lDR0dlLXhBVnpLbXg2VzUwaFZTOFZLSWppTXRCeHFXZF9Nay1hbXhTZzI4eDE5Q3ZtRGQ1ZTVLU25pbXVoVUU1d0ZrTzlIT1RhZGliTzRwclpRekNRa1dfdmE3dEhKQ2JFclc5V2pHN0xndzluX0ZhVlpoQ0c1YUF5TkZOLUswNE9tR0NDV1Q5SUE?oc=5","date":"2025-07-07","type":"pipeline","source":"Fierce Biotech","summary":"CSL trims R&D team, shifts focus toward external opportunities - Fierce Biotech","headline":"CSL trims R&D team, shifts focus toward external opportunities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1WM0lFQ01KdU1HLXAwSW9CdEJ2eWRVa3h3TWstMDBNb29zbWRza0oyd1VpMHBtLTJmOG1xOTRLUk50NDVrLWotbWZBYTU5NEVlMUpoRk5YTlJTYlRJRE9jUWFySkFjRG1BUVNsM2xhR0d0SHdzWGw4ONIBfkFVX3lxTE9lcE44WjRlWW44YldibFdmSE82S1BzNWwzT09RVzJLRXp6cmNnd2xtMW5VcGY5M3NURndnM0pYWXdhdkxiOXVfSjc4N29jQS1PQTB2b2JmdmJ2OTRTOUxmbWxhNmFGdWtWRFhzVkFrMWY3bmxzekZpRExUQTVZUQ?oc=5","date":"2025-04-23","type":"pipeline","source":"Romania Insider","summary":"Ukraine’s Biopharma Plasma plans EUR 37 mln immunoglobulin factory in western Romania - Romania Insider","headline":"Ukraine’s Biopharma Plasma plans EUR 37 mln immunoglobulin factory in western Romania","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNNTE1SzJIYVJTNzRvd0x5UkNjeThYcGNOZ2xRaGttTkUzR1lNdjUwcHp4bTc3UFRDWEJON2JMU1Fzb1JxcTRTcU1ydDlubkhldExZcUhhNHNrcGt5Yk8tZmFSaFI4OVFyc2t2STZJZHdYTHRKamxxM3FIZTR3TnhnNmFpVk56MHExTlg0cTVmX04tUHRxNmc0S1FXUWI2bEhkd1JhWlN30gGrAUFVX3lxTE5wYlJQa2diSmJzZlBiTWJvRURyZE4wMkxoQ1pUS25tRFhDYS1FR1ZKbk5PWXBnTDgtVXlnVjRXSmVZd3BxQ1NxUjhoRjdsNjF1aDhQczVpM3pzVTRocmZmYjhTVTRCUnpaVHRVc0tNdC1qM0FpR0RhYWxuN0N2V3F2dkpJNDRzd1RNb0xSSXRMdHhYR1hqb1NSY0hxQkZ6WGtqVkc3clhRd213TQ?oc=5","date":"2025-04-22","type":"pipeline","source":"The Romania Journal","summary":"Ukrainian company to build plasma medicines facility in Romania - The Romania Journal","headline":"Ukrainian company to build plasma medicines facility in Romania","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOMDF2bUQ3bmJGZmlkTm4zNHI1RzlBcmM0MG5kR0M5dVlGZDRWOUVFXzlnZVZQc0pBUmFscjlYa0VBamRKRkdrVnNrWjU2SVpoTzVXS0lsblJkclEtcTFlb3BoVGJmNEVPcnZvbHBRRHIwNC1icUhBVThFUkJyX2k2Z1hNSnJzMzdpdnRGd25lU2JDMDVMeVFUQzU1WnlkRW1DaFcydzNETWw4YTh0TVFqYk4xcXZrYTZSRUJncWZmNEphYlRyY3gxb0poU2FwMjRaNGc?oc=5","date":"2025-04-14","type":"pipeline","source":"PR Newswire UK","summary":"Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity - PR Newswire UK","headline":"Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOR3plZmoyUHVNQkhrbGFBakxEWENLYV81RW1sM2dDOXVsd3NBaVhLNGd3RS1RNkZkX0llMnh4NjZ4RjNIOF9NOFpGVDdURDlmc3Bpb3dhZGgwRFNwRUJ1d2tTRDNXT1IzVzRTc05wU21NUFJtcXMwZlpkRDYwM2lVSkpnbmhTYnhRNzlmb19BQmFEa2ZZN0k4cnBxT0ZnX2RCOFNtc0Z1Y3VOOENuU3c?oc=5","date":"2021-06-28","type":"deal","source":"newswire.com","summary":"LFB Plasma Acquires ImmunoTek Bio Center in Greenacres and Establishes Flagship Office in Florida - newswire.com","headline":"LFB Plasma Acquires ImmunoTek Bio Center in Greenacres and Establishes Flagship Office in Florida","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPV0hZaUFfUHFoWlRickl1UVpUWXptdFVPWEU4TUxrdkhraklORWR4azJLWXRMOGlqR1B2bk9GVWRqd1BBbXB1aTIyNmw1V3Yza3I3YXZKb1NiT1YyVjZCVDY1OGVZVkpHV0RrR3lVeUNBcGphT2VROHhGZEFfSlpNZ3h3Zm1sQmppNTBVUlVDMEVSb19TUnc?oc=5","date":"2019-11-08","type":"pipeline","source":"Fortune Business Insights","summary":"Plasma Fractionation Market Size, Share | Global Report [2034] - Fortune Business Insights","headline":"Plasma Fractionation Market Size, Share | Global Report [2034]","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}